679 related articles for article (PubMed ID: 27765666)
41. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
[TBL] [Abstract][Full Text] [Related]
42. Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
Perrier M; Charpentier C; Peytavin G; Lê M; Blondel L; Visseaux B; Joly V; Pinto A; Matheron S; Yazdanpanah Y; Descamps D; Landman R
J Antimicrob Chemother; 2017 Jun; 72(6):1745-1751. PubMed ID: 28186251
[TBL] [Abstract][Full Text] [Related]
43. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.
Ogbuagu O
Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1113-1126. PubMed ID: 27797606
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetic and bioequivalence evaluation of single-tablet and separate-tablet regimens for once-daily cobicistat-boosted elvitegravir in healthy Japanese male subjects: A randomized, two-way crossover study.
Shiomi M; Matsuki S; Ikeda A; Ishikawa T; Nishino N; Kimura M; Kumagai Y; Irie S
Clin Pharmacol Drug Dev; 2015; 4(3):218-25. PubMed ID: 27140802
[TBL] [Abstract][Full Text] [Related]
45. Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.
Perez-Valero I; Llibre JM; Castagna A; Pulido F; Molina JM; Esser S; Margot N; Shao Y; Temme L; Piontkowsky D; McNicholl IR; Haubrich R
J Acquir Immune Defic Syndr; 2021 Apr; 86(4):490-495. PubMed ID: 33315694
[TBL] [Abstract][Full Text] [Related]
46. Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF.
Mills A; Garner W; Pozniak A; Berenguer J; Speck RM; Bender R; Nguyen T
Patient; 2015 Aug; 8(4):359-71. PubMed ID: 26045359
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
Baldin G; Ciccullo A; Capetti A; Rusconi S; Sterrantino G; Cossu MV; Giacomelli A; Lagi F; Latini A; Bagella P; De Luca A; Di Giambenedetto S; Madeddu G
HIV Med; 2019 Feb; 20(2):164-168. PubMed ID: 30457197
[TBL] [Abstract][Full Text] [Related]
48. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
[TBL] [Abstract][Full Text] [Related]
49. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C; DeJesus E; Sax PE; Arribas JR; Gupta SK; Martorell C; Stephens JL; Stellbrink HJ; Wohl D; Maggiolo F; Thompson MA; Podzamczer D; Hagins D; Flamm JA; Brinson C; Clarke A; Huang H; Acosta R; Brainard DM; Collins SE; Martin H; ;
Lancet HIV; 2020 Jun; 7(6):e389-e400. PubMed ID: 32504574
[TBL] [Abstract][Full Text] [Related]
50. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
[TBL] [Abstract][Full Text] [Related]
51. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
Pozniak A; Arribas JR; Gathe J; Gupta SK; Post FA; Bloch M; Avihingsanon A; Crofoot G; Benson P; Lichtenstein K; Ramgopal M; Chetchotisakd P; Custodio JM; Abram ME; Wei X; Cheng A; McCallister S; SenGupta D; Fordyce MW;
J Acquir Immune Defic Syndr; 2016 Apr; 71(5):530-7. PubMed ID: 26627107
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.
Nozza S; Poli A; Ripa M; Galli L; Chiappetta S; Spagnuolo V; Rovelli C; Lazzarin A; Castagna A; Tambussi G
J Antimicrob Chemother; 2017 Feb; 72(2):632-633. PubMed ID: 27798217
[No Abstract] [Full Text] [Related]
53. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
[TBL] [Abstract][Full Text] [Related]
54. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Sax PE; DeJesus E; Mills A; Zolopa A; Cohen C; Wohl D; Gallant JE; Liu HC; Zhong L; Yale K; White K; Kearney BP; Szwarcberg J; Quirk E; Cheng AK;
Lancet; 2012 Jun; 379(9835):2439-2448. PubMed ID: 22748591
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial.
Chinula L; Ziemba L; Brummel S; McCarthy K; Coletti A; Krotje C; Johnston B; Knowles K; Moyo S; Stranix-Chibanda L; Hoffman R; Sax PE; Stringer J; Chakhtoura N; Jean-Philippe P; Korutaro V; Cassim H; Fairlie L; Masheto G; Boyce C; Frenkel LM; Amico KR; Purdue L; Shapiro R; Mmbaga BT; Patel F; van Wyk J; Rooney JF; Currier JS; Lockman S;
Lancet HIV; 2023 Jun; 10(6):e363-e374. PubMed ID: 37167996
[TBL] [Abstract][Full Text] [Related]
56. Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.
Bonora S; Calcagno A; Trentalange A; Di Perri G
Expert Opin Pharmacother; 2016; 17(3):409-19. PubMed ID: 26642079
[TBL] [Abstract][Full Text] [Related]
57. Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
Gallant J; Brunetta J; Crofoot G; Benson P; Mills A; Brinson C; Oka S; Cheng A; Garner W; Fordyce M; Das M; McCallister S;
J Acquir Immune Defic Syndr; 2016 Nov; 73(3):294-298. PubMed ID: 27171740
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients.
Huang YS; Cheng CY; Liou BH; Lu PL; Cheng SH; Lee YT; Liu CE; Sun HY; Yang CJ; Tang HJ; Lin SP; Ho MW; Huang SH; Tsai HC; Lee CH; Hung CC;
J Acquir Immune Defic Syndr; 2021 Apr; 86(4):473-481. PubMed ID: 33273214
[TBL] [Abstract][Full Text] [Related]
59. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Deeks ED
Drugs; 2018 Jul; 78(10):1013-1024. PubMed ID: 29915897
[TBL] [Abstract][Full Text] [Related]
60. Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.
Pozniak A; Flamm J; Antinori A; Bloch M; Ward D; Berenguer J; Cote P; Andreatta K; Garner W; Szwarcberg J; Nguyen-Cleary T; McColl DJ; Piontkowsky D
HIV Clin Trials; 2017 Jul; 18(4):141-148. PubMed ID: 28689453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
